ZAODX World Cancer Early Screening Conference is the world's first international conference with "tumor early screening" as the core throughout the entire process. It will focus on the research and development and transformation and application of global early screening cutting-edge technologies, from "world pattern", "China exploration", "solution" From the three perspectives of "Program", we will conduct in-depth discussions around the three major aspects of "technological power", "productivity" and "market power" to build the world's top communication platform and help the industry improve its ability to transform and apply scientific and technological achievements.
Here, we sincerely invite scientists, entrepreneurs and other people from all walks of life in the field of early cancer screening to participate in this grand event, chart the future, promote the development of early cancer screening, and work together to help achieve the goals of the "Healthy China" cancer prevention and control action.
Company Profile✦
BGI is a technology company driven by technological innovation, based on advanced technology, complete configuration and leading scale of multi-omics output platform, covering the entire industry chain and all application fields. Adhering to the vision of "Gene Technology Benefiting Humanity", with the starting point of promoting the progress of life science research, the application of life big data and improving the global medical and health level, based on the research results in the genetic field and the application of accurate detection technology in people's livelihood and health, we will implement the "prevention of greater than normal" In line with the tumor prevention and control policy of "treating", BGI makes full use of its independent sequencing platform, core precision data and algorithms to implement a closed-loop plan that "targets early diagnosis and early treatment of precancerous lesions and is supported by the Internet platform", Achieve a comprehensive solution of "screening, diagnosis, protection, treatment and monitoring" throughout the entire life cycle of cancer.
BGI is headquartered in Shenzhen, China. It has branches and medical laboratories in major domestic cities such as Beijing, Tianjin, Wuhan, Shanghai, Guangzhou, and Hong Kong, and has overseas centers and laboratories in Europe, America, Asia-Pacific and other regions. The core laboratory has formed a network layout that “covers the whole country and radiates around the world”. The company mainly serves domestic and foreign scientific research schools, research institutes, independent medical testing laboratories, pharmaceutical companies and other institutions, as well as domestic and foreign hospitals at all levels, physical examination institutions and other medical and health institutions, corporate customers and mass customers. At present, the company's business has covered more than 100 countries and regions around the world, including more than 2,000 scientific research institutions and more than 2,300 medical institutions in China; it has cooperated with more than 3,000 overseas medical and scientific research institutions in Europe, America, Asia-Pacific and other regions.
product recommendation✦
Huachangkang® Stool DNA Methylation Test
Huachangkang® uses gene detection technology to detect methylation levels of 3 bowel cancer marker genes in DNA carried in stool, Evaluate the risk of subjects suffering from intestinal cancer and precancerous lesions.
1. Multi-gene fecal DNA detection technology for specific loci in the Chinese population has better detection performance;
2. Self-sampling at home, non-invasive and painless, simple and convenient, suitable for large population screening;
3. Can provide one-stop "screening diagnosis" "Preservation and Treatment" one-stop closed-loop solution and an overall solution for colorectal cancer screening suitable for large population screening
Huaganing®Non-invasive liver cancer gene detection
Huaganing® adopts the world's leading cfDNA liquid biopsy technology, based on clinical Cohort study , selected the liver cancer methylation marker gene combination with core independent intellectual property rights. By detecting abnormal methylation signals carried by cfDNA and analyzing statistical models, the risk of subjects suffering from liver cancer is determined. can truly realize non-invasive and real-time risk monitoring of liver cancer among high-risk groups of liver cancer, and facilitate early and accurate clinical diagnosis of liver cancer.
1, affordable price: hundred yuan level cfDNA liquid biopsy product
2, excellent performance: based on cfDNA methylation markers, the sensitivity is significantly better than alpha-fetoprotein (AFP), improving the detection rate of early liver cancer
3, non-invasive detection: can Conduct multiple monitoring for high-risk groups of liver cancer (hepatitis B/ liver cirrhosis patients, etc.), real-time monitoring of liver cancer risk
4, specific sites: liver cancer methylation markers with core independent intellectual property rights selected based on large-sample clinical cohort studies Biogene combination
5, advanced technology: based on the internationally leading high-precision cfDNA methylation variation detection technology
Breast cancer/ovarian cancer susceptibility gene BRCA1/2 genetic risk assessment
Breast cancer /ovarian cancer susceptibility gene BRCA1/2 inheritance The risk assessment uses second-generation high-throughput sequencing technology to detect the BRCA1/2 full gene sequence of hereditary breast cancer /ovarian cancer 17,000+ bases in the subject to assess the risk of hereditary breast cancer/ Genetic risk profiles for ovarian cancer.
1, sensitivity and specificity are as high as 99% or above.
2, you can choose saliva or blood for testing.
3. One-on-one professional genetic counseling services will be provided for high-risk results.
4, the report will be issued in 10-15 working days.
Cervical cancer screening-HPV typing gene test
Cervical cancer screening-HPV typing gene test is developed based on the second generation high-throughput sequencing technology. It is highly related to cervical cancer announced by the World Health Organization Related 14 high-risk HPV7 (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 2 low-risk HPV7 (6, 11) Type.
1. Applicable to hospital scenarios (doctors take samples) and self-sampling scenarios (subjects take samples by themselves)
2. Suitable for two preservation media (cell preservation solution + solid sample preservation medium)
3. High sensitivity and specificity
4. Throughput High, is suitable for large-scale population screening
Meet
Early Screening Conference
BGI invites people from all walks of life to meet at the ZAODX World Cancer Early Screening Conference. From July 15th to 17th, let’s meet in Guangzhou, Guangdong, see you there!
jointly participate in this grand event and shape the future!
